SURGLINE will expand its business model to include driving new revenues to physician practices via its launch of a physician in-office allergy testing program starting July 1, 2014.
The program will drive down the cost of care for allergy therapy in the U.S. marketplace while driving new revenues to physicians.
WEST PALM BEACH, Fla., June 2, 2014 SurgLine International, Inc. (SGLN.PK)
SurgLine International, Inc. and its wholly owned subsidiary SurgLine Inc. will launch a physician office allergy testing program using Sublingual Immunotherapy also known as SLIT commencing July 1, 2014.
• It is estimated that 58% of patients suffering from allergies visit their primary care provider first.
• 54.6% of Americans are allergic to at least two allergens.
• The supply of allergists is expected to decline while the demand for allergists is expected to continue to rise.
• Our SLIT in-office testing program will decrease the cost of allergy and asthma care by up to 80% over traditional steroid therapy.
SurgLine will be one of the first companies in the United States to launch this highly effective allergy testing and treatment program.
It is estimated that there are 300,000 plus primary care physicians practicing in the U.S. alone that can administer the SurgLine Allergy program.
It is estimated that more than 150 million people suffer from allergies and or asthma.
SurgLine will also focus on targeting managed care payers seeking to reduce the cost of allergy and asthma care that traditionally includes allergy shots and steroids.
The SurgLine Allergy program will offer patients the opportunity to administer a drop each morning under the tongue in place of allergy shots.
This therapy program will drive new revenues to primary care physicians while driving down the total cost of care. The average primary care physician can materially improve his or her practice profitability with our SLIT Allergy program.
These new revenues are anticipated to allow the company to generate new cash flow opportunities while pursuing its cost savings model for savings to surgery centers and hospitals.
McKesson is the registered trademark of McKesson Corporation and Henry Schein is the registered trademark of Henry Schein, Inc.
SurgLine continues to participate in the MedPassage ecosystem and anticipates that the MedPassage ecosystem will continue to gain market share awareness in the coming year to which SurgLine will benefit from sale of its products and aggressive pricing strategies.
Keywords: Henry Schein, McKesson, Medical, Dental, Veterinarian, Hospitals, Clinics, Physician, Practices, Savings, Laboratories, SurgLine, SurgLinesavings.com, Savings, direct ship.
Forward Looking Statements
This update release may contain forward-looking statements, including information about management’s view of future expectations, plans and prospects for SurgLine International, Inc. (the "Company"). In particular, when used in the preceding discussion, the words "predicts", "believes", "expects", "intends", "seeks", "estimates", "plans", "anticipates", and similar conditional expressions or future or conditional verbs such as "will", "may", "might", "should" "would" and "could" are intended to identify forward-looking statements. In addition, our representatives may from time to time make oral forward-looking statements. Any such statements, other than those of historical fact, about an action, event or development are forward-looking statements. Such statements are based on the current expectations and certain assumptions of the Company’s management. Such statements are, therefore, subject to a variety of known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, which could cause the actual results, performance, its subsidiaries and concepts to be materially different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance or achievements may vary materially from those described in the relevant forward-looking statements as bine expected, anticipated, intended, planned, believed, sought, estimated or projected. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included herein are made only as of the date hereof. The company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the company undertakes no obligation to update or revise these forward-looking statements to reflect the impact of circumstances or events that arise after the date of the forward-looking statement was made, except as required by law, and also takes no obligation to update or correct information prepared by third parties that re not paid for by the Company. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed under item, "Risk Factors" of the Company’s annual Report on Form 10-K for the year ended July 31, 2014 and in any of the Company’s other subsequent Securities and Exchange Commission filings.
